What is TARGET RWE?
Headquartered in Durham, North Carolina, Target RWE operates at the intersection of advanced epidemiology and healthcare technology. Founded in 2015, the company specializes in the generation of real-world evidence (RWE) that supports the entire lifecycle of therapeutic products. Through its proprietary platforms, such as causalRisk and causalPHR, the firm delivers regulatory-grade analyses derived from longitudinal patient registries. These datasets are essential for pharmaceutical and life sciences partners aiming to optimize post-marketing surveillance, pharmacovigilance, and label expansion. By capturing comprehensive patient journeys across both academic and community care settings, Target RWE provides the granular insights necessary to address chronic conditions in fields like gastroenterology and dermatology, ensuring that clinical decisions are backed by robust, actionable evidence.
How much funding has TARGET RWE raised?
TARGET RWE has raised a total of $637K across 1 funding round:
Private Equity
$637K
Private Equity (2016): $637K, investors not publicly disclosed
Key Investors in TARGET RWE
Undisclosed Investor
An institutional capital partner focused on scaling high-growth healthcare technology and life sciences infrastructure firms.
Undisclosed Investor
A private equity firm specializing in long-term value creation within the pharmaceutical services and clinical research sectors.
Undisclosed Investor
A strategic investment group providing growth capital to companies developing proprietary data analytics for the healthcare industry.
What's next for TARGET RWE?
With the backing of this significant capital, Target RWE is well-positioned to scale its analytical capabilities and expand its footprint in the European and United States markets. The company's strategic roadmap likely involves enhancing its causal inference methodologies to further refine the predictive power of its datasets. As regulatory bodies increasingly prioritize real-world data in their decision-making processes, Target RWE is poised to capitalize on the shift toward evidence-based medicine. Future growth will likely focus on deepening its therapeutic expertise and integrating more diverse data streams to maintain its competitive edge in the rapidly evolving landscape of healthcare analytics and drug development support.
See full TARGET RWE company page
